110 related articles for article (PubMed ID: 10081698)
21. Neoadjuvant hormone therapy: the Canadian trials.
Klotz L; Gleave M; Goldenberg SL
Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients.
Schmid HP; Semjonow A; Aus G; Hertle L
Urol Int; 2000; 65(2):63-7. PubMed ID: 11025425
[TBL] [Abstract][Full Text] [Related]
23. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
24. Is neoadjuvant hormonal therapy before radical prostatectomy indicated?
Chun J; Pruthi RS
Urol Int; 2004; 72(4):275-80. PubMed ID: 15153722
[TBL] [Abstract][Full Text] [Related]
25. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
27. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Andros EA; Danesghari F; Crawford ED
Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience.
Fair WR; Scher HI
Surg Oncol Clin N Am; 1997 Oct; 6(4):831-46. PubMed ID: 9309096
[TBL] [Abstract][Full Text] [Related]
30. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
Tokunaga M; Yasuda M; Osamura RY; Itoh J; Mukai M; Shima M; Usui Y; Masuda A; Miyakita H; Terachi T
Oncol Rep; 2005 Jun; 13(6):1081-7. PubMed ID: 15870925
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
32. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
33. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Tunn UW; Acar O; Goldschmidt AJ
Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
[TBL] [Abstract][Full Text] [Related]
34. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
35. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
36. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
Gomella LG; Zeltser I; Valicenti RK
Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
[TBL] [Abstract][Full Text] [Related]
37. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Tran TA; Jennings TA; Ross JS; Nazeer T
Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
[TBL] [Abstract][Full Text] [Related]
38. [What is the best strategy of hormonal therapy in the treatment of locally advanced prostate cancer?].
Ehara H; Nakano M; Deguchi T
Hinyokika Kiyo; 2006 Jun; 52(6):473-7. PubMed ID: 16848361
[TBL] [Abstract][Full Text] [Related]
39. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.
Klotz LH; Goldenberg SL; Jewett MA; Fradet Y; Nam R; Barkin J; Chin J; Chatterjee S;
J Urol; 2003 Sep; 170(3):791-4. PubMed ID: 12913699
[TBL] [Abstract][Full Text] [Related]
40. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
